RECRUITING Not applicable ClinicalTrials.gov

Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia

Sponsor: Pasquale Santangeli • ClinicalTrials.gov ID: NCT06891456

Registry updated: 2026-09-03

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator (ICD). The study hypothesis is that the PFA ablation is more efficient compared to the RFA technique but retains a comparable safety profile.

Interventions

RFA Ablation (Device)
RFA ablation of VT substrate using FlexAbility or ThermoCool ST catheter
PFA Ablation (Device)
PFA ablation of VT substrate using FARAPOINT catheter

Eligibility criteria

Inclusion Criteria: must meet all of the following: 1. Age ≥18 years. 2. Ischemic heart disease with prior myocardial infarction. 3. Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment. 4. Documented sustained monomorphic VT with any of the following characteristics: 1. ≥2documented episodes in patients with implantable cardioverter defibrillators (ICD) 2. ≥1 documented episode(s) in patients without ICD 3. Recurrent VT despite antiarrhythmic medications (ineffective, contraindicated or not tolerated) or ICD interventions 5. Provision of signed and dated informed consent form. 6. Stated willingness to comply with all study procedures and availability for the duration of the study. Exclusion Criteria: any of the following: 1. Unable to provide informed consent. 2. Idiopathic VT. 3. Mobile LV thrombus. 4. Acute coronary syndrome within the preceding 2 months (if incessant VT ≥1 month before enrollment). 5. Comorbidity likely to limit survival to \<12 months 6. New York Heart Association class IV heart failure. 7. Estimated glomerular filtration rate \<30 ml/min/1.73m2. 8. Thrombocytopenia or coagulopathy. 9. Contraindication to heparin. 10. Pregnancy or lactation. 11. Cardiac surgery within the past 2 months. 12. Active infection. 13. Clinical, laboratory or imaging evidence of active ischemia. 14. Severe left heart valvular heart disease (aortic/mitral stenosis or regurgitation). 15. Any concomitant congenital heart disease. 16. Prior catheter or surgical ablation of VT within the past 2 months. 17. Anticipated need for epicardial mapping and ablation. 18. For individuals with no pre-existing ICD: Ineligibility for an ICD implant. 19. Pre-existing LVAD or other hemodynamic assist device 20. Present mechanical heart valve 21. cardiogenic shock unless it is due to incessant VT

Conditions

Ventricular Tachycardia Ischemic Heart Disease Sustained VT

Locations

Cleveland Clinic — Cleveland, Ohio, United States

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment